Circulation最新文献

{"title":"Vagal Nerve Stimulation for Cardiovascular Diseases: From Hype to Hope","authors":"Stavros Stavrakis","doi":"10.1161/circulationaha.125.078579","DOIUrl":"https://doi.org/10.1161/circulationaha.125.078579","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"9 1","pages":"1287-1289"},"PeriodicalIF":37.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149092289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rigosertib Reverses Hypertrophic Cardiomyopathy in Noonan Syndrome.","authors":"Levi Legler, Katya Marchetti, Bing Xu, Tara Keshavarz Shirazi, Sereene Kurzum, Chase W Kessinger, Izabella Vredenburg, Yan Sun, Frank A Dinenno, Damian Bohler, Angelika G Aleman, Nelson A Rodriguez, Simon Ng, Sophie Gao, Angela Wang, Mayte Suarez-Farinas, Hung-Mo Lin, Tirtha Das, Karen Ocorr, Ross L Cagan, Bruce D Gelb, Maria I Kontaridis","doi":"10.1161/CIRCULATIONAHA.126.080188","DOIUrl":"10.1161/CIRCULATIONAHA.126.080188","url":null,"abstract":"<p><strong>Background: </strong>RASopathies constitute a group of rare genetic disorders caused by mutations in genes along the canonical RAS/mitogen-activated protein kinase (MAPK) signaling pathway, affecting cell growth and differentiation. These syndromes, which include Noonan syndrome (NS), are characterized by developmental delays, distinctive facial dysmorphia, and cardiac defects, notably hypertrophic cardiomyopathy (HCM). Despite their prevalence and impact, therapeutic options for RASopathies remain limited. Rigosertib, a novel dual RAS/MAPK and phosphatidylinositol 3-kinase (PI3K)/AKT pathway inhibitor, is currently in clinical trials for treatment of melanoma and recessive dystrophic epidermolysis bullosa. Here, we identify rigosertib as a candidate therapy for RAF1-associated HCM.</p><p><strong>Methods: </strong>We performed a drug screen of clinically relevant compounds in transgenic <i>Drosophila</i> models of RASopathies to identify candidate therapeutics. Cardiac-targeted <i>Drosophila</i> models expressing RASopathy-associated transgenes were used to evaluate the effects of rigosertib on cardiac hypertrophy and compare its efficacy with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Therapeutic efficacy was further assessed in a mammalian model using <i>Raf1</i><sup><i>L613V/+</i></sup> knock-in mice treated with rigosertib for 6 weeks. Cardiac structure and function were evaluated by echocardiography, histology, and molecular analyses, including assessment of cardiomyocyte size, fetal gene expression, and extracellular signal-regulated kinase/AKT signaling. Additional NS-associated phenotypes, including skeletal growth and craniofacial abnormalities, were also evaluated.</p><p><strong>Results: </strong>Rigosertib was effective across a panel of transgenic <i>Drosophila</i> RASopathy models, suggesting activity against multiple disease variants. In cardiac-targeted fly models, rigosertib reduced cardiac hypertrophy and outperformed trametinib. In <i>Raf1</i><sup><i>L613V/+</i></sup> mice, 6 weeks of treatment significantly improved left ventricular chamber dimension, posterior wall thickness, heart mass, and cardiomyocyte size, resulting in reversal of cardiac hypertrophy. Rigosertib also normalized fetal gene expression and inhibited extracellular signal-regulated kinase and AKT signaling in primary cardiomyocytes. In addition to reversing cardiac pathology, rigosertib significantly improved other NS-associated features, including increased bone growth and correction of craniofacial abnormalities.</p><p><strong>Conclusions: </strong>Together, our findings suggest that rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features, supporting its development as a promising treatment for RAF1-associated HCM and, potentially, other RASopathy-dependent pathologies. This study not only highlights the therapeutic potential of rigosertib but also demonstrates the utility","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1322-1338"},"PeriodicalIF":41.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13496009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Considerations for the Care of the Tactical Athlete With Cardiovascular Abnormalities: A Scientific Statement From the American College of Cardiology and the American Heart Association.","authors":"Elizabeth H Dineen, Mark C Haigney, Benjamin D Levine, Michael J Ackerman, Aaron L Baggish, Travis C Batts, Alan C Braverman, Eugene H Chung, Geoffrey J Cole, William K Cornwell, Eddie Davenport, Peter N Dean, Harry C Dietz, Alexander Eastman, Marc Alaric Franzos, J Sawalla Guseh, Travis E Harrell, Edward A Hulten, Cynthia A James, Jonathan H Kim, Rachel J Lampert, Matthew W Martinez, Joseph W May, Francis G O'Connor, Bradley J Petek, Ankit B Shah, Denise L Smith, Paul D Thompson, Meagan M Wasfy, James A Watts","doi":"10.1161/CIR.0000000000001476","DOIUrl":"10.1161/CIR.0000000000001476","url":null,"abstract":"<p><strong>Aim: </strong>The American College of Cardiology/American Heart Association Scientific Statement, \"Clinical Considerations for the Care of the Tactical Athlete With Cardiovascular Abnormalities,\" was written to provide guidance and education for clinicians caring for the tactical athlete (ie, firefighters, law enforcement officers, military) with cardiovascular disease or risk for cardiovascular disease, and for the organizations overseeing the care and wellness of these athletes. The considerations are shaped by the interaction between occupational demands and fit for full duty assessments, including risk discussions about how a cardiovascular event in a tactical athlete could impact teammates' well-being, community safety, and overall mission success.</p><p><strong>Methods: </strong>This scientific statement is organized into 11 sections focused on cardiovascular disease processes and other topics that are relevant when considering the potential risks and benefits of performing tasks specific to the tactical athlete. Task forces, comprised of experts in tactical athlete domains, sports cardiology, and the respective topics covered, were assigned to each section, and specific \"Clinical Considerations Tables\" for clinicians to reference were prepared. Comprehensive literature reviews and an emphasis on tactical athlete-focused data, as available, were integral in the writing of all clinical considerations presented. The framework mirrors that of the recently published, \"Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology.\"</p><p><strong>Structure: </strong>The specific sections in this document include: Section 1: Tactical Tasks Classification; Section 2: The Tactical Athlete Preparticipation Cardiac Evaluation; Section 3: Ethical and Legal Aspects of Tactical Clinical Management; Section 4: Genetic Cardiomyopathies; Section 5: Myocarditis and Other Acquired Cardiac Conditions; Section 6: Congenital Heart Disease; Section 7: Aortopathy, Bicuspid Aortic Valve, and Spontaneous Coronary Artery Dissection; Section 8: Syncope, SCA, Arrhythmias, and Devices; Section 9: Cardiac Channelopathies; Section 10: Older Tactical Athlete; Section 11: Environmental Exposures, PED/S, and Additional Cardiac Conditions and Considerations. Each section provides a summary detailing the rationale for key clinical considerations and the respective Clinical Considerations Table(s).</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"e524-e572"},"PeriodicalIF":41.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter by Lu Regarding Article, “Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes”","authors":"Cheng-Wei Lu","doi":"10.1161/circulationaha.126.079792","DOIUrl":"https://doi.org/10.1161/circulationaha.126.079792","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"15 1","pages":""},"PeriodicalIF":37.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy: Global Insights From Worldwide Registries","authors":"Pamela K. Mason,Christopher M. Kramer","doi":"10.1161/circulationaha.126.079687","DOIUrl":"https://doi.org/10.1161/circulationaha.126.079687","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"404 1","pages":"1306-1308"},"PeriodicalIF":37.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response by Cho et al to Letters Regarding Article, “Association of Statin Discontinuation in Pregnancy with Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study”","authors":"Yongtai Cho,Danbee Kang,Ju-Young Shin,Ki Hong Choi","doi":"10.1161/circulationaha.126.081467","DOIUrl":"https://doi.org/10.1161/circulationaha.126.081467","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"11 1","pages":""},"PeriodicalIF":37.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Important Residual Lesions and Early Unplanned Reinterventions After Pediatric Cardiac Surgery: A Scientific Statement From the American Heart Association.","authors":"John M Costello, Mjaye L Mazwi, Christine M Riley, Cesar E Gonzalez de Alba, Laura J Olivieri, Cynthia K Rigsby, Kevin D Hill, Emile Bacha, Jane W Newburger, Meena Nathan","doi":"10.1161/CIR.0000000000001465","DOIUrl":"10.1161/CIR.0000000000001465","url":null,"abstract":"<p><p>Optimal outcomes for congenital heart surgery depend on the expertise and judgment of an integrated multidisciplinary clinical team. The best outcomes require a comprehensive understanding of the patient's anatomy and physiology, an appropriate therapeutic plan, a meticulously executed operation that is technically optimal and facilitated by lesion-specific anesthesia and perfusion strategies, and skilled perioperative care. A principal factor contributing to adverse outcomes is the presence of important residual lesions after surgery, which may necessitate early unplanned cardiac reinterventions during the index hospitalization. Such reinterventions occur in ≈5% of all pediatric cardiac operations, with a higher incidence in younger patients and more complex procedures. The presence of significant residual lesions and the need for unplanned reinterventions are strongly associated with increased morbidity, mortality, and resource use. Wide center-level variation in the incidence and timing of unplanned reinterventions suggests an opportunity for quality improvement. In this scientific statement, we summarize the incidence, risk factors, and clinical outcomes of important residual lesions and early unplanned cardiac reinterventions. We review postoperative monitoring strategies and clinical indicators suggestive of a residual lesion, and we provide an overview of the noninvasive imaging modalities used for their identification and quantification. The roles of diagnostic and interventional cardiac catheterization in the management of residual lesions are discussed, along with surgical considerations for early reoperation. We highlight the importance of communication with patients and families. Last, key areas for future investigations are identified.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"e573-e588"},"PeriodicalIF":41.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy.","authors":"Ethan J Rowin, Barry J Maron, Konstantinos C Siontis, Albree F Tower-Rader, Daniele Massera, Benjamin Koethe, Ozlem Bilen, Dermot Phelan, Ahran Arnold, Jagdeep S Mohal, Amanda M Varnava, Maria Alessandra Schiavo, Raffaello Ditaranto, Elena Biagini, Hisham Ahamed, Aparna Hari, Sofian Johar, Lau Bee-Ngo, Domenico Corrado, Jackson O'Neill, Chris Semsarian, Susan A Casey, Scott Sharkey, Jiri Bonaventura, Jakub Honek, Alice Krebsova, Marketa Adamova, Dawn McCrystal, Erica Scherer, Ashwin Pillai, Megan Scalzo, Abhishek Jaiswal, Jorge Alberto Lax, Ruxandra Jurcut, Hiroaki Kitaok, Marit Kristine Smedsrud, Amanda Kirshkaln-Leahy, Pietro Francia, Beatrice Musumeci, Tatevik Hovakimyan, Omnia Kamel, Magdi H Yacoub, Oddný Brattberg Gunnarsdóttir, Gunnar Thor Gunnarsson, Berglind Adalsteinsdottir, Enrique A Berrios Barcenas, Michael A Fifer, Steve R Ommen, Mark V Sherrid, Martin S Maron","doi":"10.1161/CIRCULATIONAHA.125.078597","DOIUrl":"10.1161/CIRCULATIONAHA.125.078597","url":null,"abstract":"<p><strong>Background: </strong>Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population.</p><p><strong>Methods: </strong>Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes.</p><p><strong>Results: </strong>A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively.</p><p><strong>Conclusions: </strong>In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1290-1305"},"PeriodicalIF":41.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, Process of Care, and Outcomes of In-Hospital Cardiac Arrest in China: A Multicenter Prospective Registry Study","authors":"Chunyi Wang,Jiaqi Zheng,Wen Zheng,Kehui Yang,Xianliang Yan,Yage Chai,Fengying Chen,Liang Huang,Rixing Wang,Xiaotong Han,Yu Ma,Jingjing Ma,Jianbo Zhang,Yuan Bian,Kai Cheng,Rugang Liu,Chang Pan,Rui Shang,Mingjie Wang,Ruixue Song,Jiaojiao Pang,Jiali Wang,Saket Girotra,Guoqiang Zhang,Feng Xu,Yuguo Chen,Suyun Qian,Guoxing Wang,Bo Chen,Shengtao Yan,Bing Ji,Huiqiong Tan,Lijie Qin,Yimin Zhu,Peiwu Li,Yong Ming,Han Shen,Ling Zhang,Jian Zhuo,Song Chen,Shulan Huang,Zhenying Chen,Haisheng Hou,Changqing Zhu,Jie Wei,Jiazhen Wang,Zhaofen Lin,Zhide Ma,Guofeng Wu,Hongwei Shan,Tie Xu,Hong Zhang,Zhihong Lin,Chaoqian Li,Xiujie Wang,Chunshui Cao,Peng Peng,Xiaowei Liu,Wei Chong,Jihong Xing,Zonglin Guo,Youwei Pan,Honghong Pei,Guangju Zhou,Yanfen Chai","doi":"10.1161/circulationaha.126.080404","DOIUrl":"https://doi.org/10.1161/circulationaha.126.080404","url":null,"abstract":"BACKGROUND: In-hospital cardiac arrest (IHCA) is an acute event associated with high mortality. Although survival has improved in high-income countries, contemporary multicenter data from low- and middle-income countries remain scarce, limiting global benchmarking and the identification of system-level opportunities for improvement. METHODS: This cohort study used data from the BASIC-IHCA (Baseline Investigation of In-Hospital Cardiac Arrest) registry. Adult patients (≥18 years) who experienced IHCA and received cardiopulmonary resuscitation between July 1, 2019, and December 31, 2020, at 37 hospitals across 29 provinces in China were included. The primary outcome was survival to 30 days or hospital discharge. Secondary outcomes included return of spontaneous circulation, 6- and 12-month survival, and favorable neurological outcome (Cerebral Performance Category score 1–2). Process measures focused on the timeliness of resuscitation response and the implementation of postresuscitation interventions. RESULTS: Among 17 602 patients (median age, 66 years; 65.5% male), the annual incidence of adult IHCA was 4.1 per 1000 admissions. Cardiac etiology was identified in 6569 (37.3%) patients, and 2380 (13.5%) presented with initial shockable rhythm. Among all patients, 16 872 (95.9%) received cardiopulmonary resuscitation within 1 minute; timely defibrillation or epinephrine was achieved in 71.4% and 84.4% of patients with initial shockable and nonshockable rhythms, respectively. Sustained return of spontaneous circulation was achieved in 6200 (35.2%) patients, of whom 222 (3.6%) received temperature control therapy and 320 (5.2%) underwent coronary angiography. Overall, 1610 (9.1%) patients survived to 30 days or discharge, with 1241 (7.1%) having a favorable neurological outcome. At 12 months, 1075 (6.1%) patients remained alive, and 986 (5.6%) had a favorable neurological outcome. CONCLUSIONS: This multicenter registry highlights a substantial burden of IHCA in China, with markedly low survival rates. Despite prompt initial resuscitation, critical gaps persist in postresuscitation care. Systemic and cultural factors, including the infrequent use of do not attempt cardiopulmonary resuscitation orders, may further contribute to survival disparities. These findings suggest several system-level opportunities to improve IHCA outcomes, including structured response systems, optimized critical care resource allocation, and greater integration of advanced care planning.","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"167 1","pages":""},"PeriodicalIF":37.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast Cell–Derived IL-4 Induces Pathogenic Cardiac Fibroblasts in Heart Failure","authors":"Jin Komuro,Toshiyuki Ko,Masamichi Ito,Hisayuki Hashimoto,Yanfei Zhang,Takahiro Jimba,Manami Katoh,Mikako Katagiri,Masayuki Kubota,Masataka Yamasaki,Daigo Nishijo,Kaoruko Komuro,Shinsuke Yuasa,Masaki Ieda,Norihiko Takeda,Seitaro Nomura,Issei Komuro","doi":"10.1161/circulationaha.126.081083","DOIUrl":"https://doi.org/10.1161/circulationaha.126.081083","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"75 1","pages":"1378-1381"},"PeriodicalIF":37.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}